Clinical trials: General Population
Covid19 Vaccine
PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
The Vaccine Product, PTX-COVID19-B mRNA Humoral Vaccine, is intended for prevention of COVID-19 in a general population. This study is designed to evaluate the safety, tolerability, and immunogenicity of PTX-COVID19-B vaccine in…
- Trial name
- NCT04765436
- Testing
- PTX-COVID19-B
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Providence Therapeutics Holdings Inc.
Anxiety Disorders
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
- Trial name
- NCT00715039
- Testing
- lorazepam, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer
New Onset Generalized Myasthenia Gravis (gMG)
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC.
- Trial name
- ADAPT-EARLY (NCT06909214)
- Testing
- Efgartigimod PH20 SC
- Where
- 18 sites in United States
- Volunteers
- 30 people
- Sponsor
- argenx
Type 2 Diabetes, Hypertension
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases
- Conditions
- Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
- Trial name
- iCaReMe (NCT03549754)
- Where
- 76 sites in Brazil, Chile and 18 more
- Volunteers
- 35,000 people
- Sponsor
- AstraZeneca
Stroke, Atrial Fibrillation
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in…
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Trial name
- EngageAFTIMI48 (NCT00781391)
- Testing
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg)
- Where
- 1,009 sites in United States, Argentina and 44 more
- Volunteers
- 21,105 people
- Sponsor
- Daiichi Sankyo
Anesthesia, General
Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)
The objective of the trial was to show equivalence in recovery from neuromuscular block after a single dose of 4.0 mg/kg sugammadex, administered at first twitch (T1) 3-10% after continuous infusion of rocuronium, between…
- Trial name
- NCT00559468
- Testing
- Sugammadex, Rocuronium, Sevoflurane
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Anxiety Disorder (GAD)
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- NCT06846320
- Testing
- ABBV-932, Antidepressant Therapy (ADT)
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- AbbVie
Primary Pulmonary Hypertension
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT03992755
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 25 sites in United States
- Volunteers
- 92 people
- Sponsor
- Liquidia Technologies, Inc.
Chronic Obstructive Pulmonary Disease
Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America
PUMA is an observational, multicentre, multinational, cross-sectional study with primary care physicians (primary care, general and family physicians).
- Trial name
- PUMA PROJECT (NCT01493544)
- Where
- 18 sites in Argentina, Colombia and 2 more
- Volunteers
- 1,907 people
- Sponsor
- AstraZeneca
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01882647
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 11 sites in United States
- Volunteers
- 222 people
- Sponsor
- Therapeutics, Inc.
Tobacco Use
Cross-Sectional Survey on the Use of Tobacco Products - Italy
The main purpose of the research study is to estimate the prevalence of tobacco product use and describe the tobacco use patterns in adults in Italy.
- Trial name
- NCT03527004
- Testing
- Survey on Use of Tobacco Products in the General Population, Survey on Use of Tobacco Products in IQOS Users
- Where
- Switzerland
- Volunteers
- 6,107 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Hypercholesterolemia
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery…
- Trial name
- GLAGOV (NCT01813422)
- Testing
- Evolocumab
- Where
- 226 sites in United States, Argentina and 30 more
- Volunteers
- 970 people
- Sponsor
- Amgen
Anesthesia, General
Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)
The purpose of this study was to demonstrate in adult participants faster recovery from a neuromuscular block induced by either rocuronium or vecuronium after reversal at reappearance of T2 (the amplitude of the first response of…
- Trial name
- NCT00451217
- Testing
- Sugammadex, Neostigmine
- Volunteers
- 198 people
- Sponsor
- Merck Sharp & Dohme LLC